Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy

Introduction. In the structure of cancer incidence, lung cancer ranks first among men. In order to study the molecular mechanisms of the initiation and progression of lung cancer, it is necessary to study not only the tumor cells themselves, but also the features of the systemic tryptophan metabolism. Tryptophan catabolites, being to a large extent product of the metabolic activity of the intestinal microbiota, can affect the effectiveness of immunotherapy with checkpoint inhibitors. The kynurenine pathway of tryptophan metabolism is intensified in the body of cancer patients; its products have a pro-oncogenic and immunosuppressive effect, which may hinder the effectiveness of immunotherapy.

Objective – to study the dynamics of changes in various metabolites of tryptophan metabolism in the blood serum and feces of patients with non-small cell lung cancer with various effects of immunotherapy with inhibitors of PD-1 (programmed cell death receptor 1) / PD-L1 (programmed cell death receptor 1 ligand).

Materials and methods. The study included blood serum and stool samples obtained from 20 patients with non-small cell lung cancer treated with PD-1 / PD-L1 inhibitors. Using high-performance liquid chromatography with mass spectrometric analysis, the levels of 13 tryptophan metabolites were assessed in patients with various effects of immunotherapy. The significance of differences between the samples was assessed using a nonparametric method according to the Mann – Whitney test. They were considered statistically significant at p <0.05.

Results. In fecal analyzes of patients in whom a positive effect of immunotherapy was observed, baseline levels of 5-hydroxyindole acetate and quinolinic acid were lower than in patients with tumor progression. Positive clinical dynamics was accompanied by a decrease in the content of indole-3-lactate, kynurenine and indole-3-carboxaldehyde in the feces of patients. In the serum of patients with a positive response, the initial content of 5-hydroxyindole acetate, indole-3-acetate, indole-3-butyrate and quinoline acid was lower than in patients with progression of non-small cell lung cancer. A positive response to immunotherapy was characterized by an increase in the levels of indole-3-butyrate and indole-3-propionate, and a negative response was not accompanied by statistically significant changes in the studied tryptophan metabolites.

Conclusion. Profiling tryptophan metabolites in feces and serum of patients with non-small cell lung cancer can be used to predict the effectiveness of immunotherapy with PD-1 / PD-L1 inhibitors.

1. Wu Y., Chen W., Xu Z.P., Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol 2019;10:2022. DOI: 10.3389/fimmu.2019.02022.

2. Qin R., Zhao C., Wang C.J. et al. Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. J Immunother Cancer 2021;9(7):e002840. DOI: 10.1136/jitc-2021-002840.

3. Kit O.I., Vodolazhsky D.I., Maksimov A.Yu. et al. Molecular genetic and phenotypic characteristics of patients with lung adenocarcinoma among inhabitants of the south of Russia. Molekulyarnaya medicina = Molecular medicine 2016;14(6):35–40. (In Russ.).

4. Venkateswaran N., Lafita-Navarro M.C., Hao Y.H. et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev 2019;33(17–18):1236–51. DOI: 10.1101/gad.327056.119.

5. Platten M., Wick W., Van den Eynde B.J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72(21):5435–40. DOI: 10.1158/0008-5472.CAN-12-0569.

6. Walczak K., Turski W.A., Rajtar G. Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways. Amino Acids 2014;46(10):2393–401. DOI: 10.1007/s00726-014-1790-3.

7. Wan Y., Li Y., Yan C. et al. Indole: a privileged scaffold for the design of anti-cancer agents. Eur J Med Chem2019;183:111691. DOI: 10.1016/j.ejmech.2019.111691.

8. Chowdhury M.M.I., Kurata K., Yuasa K. et al. Suppression of TNFα expression induced by indole-3-acetic acid is not mediated by AhR activation in Caco-2 cells. Biosci Biotechnol Biochem 2021;85(4):902–6. DOI: 10.1093/bbb/zbaa101.

9. Sakita J.Y., Bader M., Santos E.S. et al. Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis. J Pathol 2019;249(1): 102–13. DOI: 10.1002/path.5285.

10. Walczak K., Langner E., Szalast K. et al. A tryptophan metabolite, 8-hydroxyquinaldic acid, exerts antiproliferative and anti-migratory effects on colorectal Cancer Cells. Molecules 2020;25(7):1655. DOI: 10.3390/molecules25071655.

11. Tzin V., Galili G. The biosynthetic pathways for shikimate and aromatic amino acids in arabidopsis thaliana. Arabidopsis Book 2010;8:e0132. DOI: 10.1199/tab.0132.

12. Agus A., Planchais J., Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018;23(6):716–24. DOI: 10.1016/j.chom.2018.05.003.

13. Liu Y., Liang X., Dong W. et al. Tumorrepopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation. Cancer Cell 2018;33(3):480–94.e7. DOI: 10.1016/j.ccell.2018.02.005.

14. Hsu Y.L., Hung J.Y., Chiang S.Y. et al. Lung cancer-derived galectin-1 contributes to cancer associated fibroblastmediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget 2016;7(19):27584–98. DOI: 10.18632/oncotarget.8488.

15. Grenda A., Krawczyk P. Cancer trigger or remedy: two faces of the human microbiome. Appl Microbiol Biotechnol 2021;105(4):1395–405. DOI: 10.1007/s00253-021-11125-0.

16. Peng Z., Cheng S., Kou Y. et al. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunol Res 2020;8(10):1251–61. DOI: 10.1158/2326-6066.CIR-19-1014.